ProCE Banner Activity

Podcast Pearls: Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer

Slideset Download
Download this slideset to learn more about the rationale for combining PARP inhibitors with a variety of agents including androgen receptor directed therapy, immune checkpoint inhibitors, and DNA damaging agents as discussed in our podcast.

Released: April 16, 2021

Expiration: April 15, 2022

No longer available for credit.

Share

Faculty

Karim Fizazi

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Joaquin Mateo

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Karim Fizazi, MD, PhD, has disclosed that he has received consulting fees from AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, CureVac, ESSA, Genentech, Janssen, MSD, Orion, and Sanofi.

Joaquin Mateo, MD, PhD

Medical Oncology Department
Vall d’Hebron University Hospital
Group Leader
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Joaquin Mateo, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Clovis, Guardant Health, Janssen, MSD, Pfizer, and Roche; funds for research support from AstraZeneca; and fees for non-CME/CE services from AstraZeneca, Guardant Health, Janssen, MSD, and Pfizer.